Cargando…

Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy

Cancer accounts for numerous deaths each year, and it is one of the most common causes of death worldwide, despite many breakthroughs in the discovery of novel anticancer candidates. Each new year the FDA approves the use of new drugs for cancer treatments. In the last years, the biological targets...

Descripción completa

Detalles Bibliográficos
Autor principal: Hawash, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776383/
https://www.ncbi.nlm.nih.gov/pubmed/36551271
http://dx.doi.org/10.3390/biom12121843
_version_ 1784855852076761088
author Hawash, Mohammed
author_facet Hawash, Mohammed
author_sort Hawash, Mohammed
collection PubMed
description Cancer accounts for numerous deaths each year, and it is one of the most common causes of death worldwide, despite many breakthroughs in the discovery of novel anticancer candidates. Each new year the FDA approves the use of new drugs for cancer treatments. In the last years, the biological targets of anticancer agents have started to be clearer and one of these main targets is tubulin protein; this protein plays an essential role in cell division, as well as in intracellular transportation. The inhibition of microtubule formation by targeting tubulin protein induces cell death by apoptosis. In the last years, numerous novel structures were designed and synthesized to target tubulin, and this can be achieved by inhibiting the polymerization or depolymerization of the microtubules. In this review article, recent novel compounds that have antiproliferation activities against a panel of cancer cell lines that target tubulin are explored in detail. This review article emphasizes the recent developments of tubulin inhibitors, with insights into their antiproliferative and anti-tubulin activities. A full literature review shows that tubulin inhibitors are associated with properties in the inhibition of cancer cell line viability, inducing apoptosis, and good binding interaction with the colchicine binding site of tubulin. Furthermore, some drugs, such as cabazitaxel and fosbretabulin, have been approved by FDA in the last three years as tubulin inhibitors. The design and development of efficient tubulin inhibitors is progressively becoming a credible solution in treating many species of cancers.
format Online
Article
Text
id pubmed-9776383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97763832022-12-23 Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy Hawash, Mohammed Biomolecules Review Cancer accounts for numerous deaths each year, and it is one of the most common causes of death worldwide, despite many breakthroughs in the discovery of novel anticancer candidates. Each new year the FDA approves the use of new drugs for cancer treatments. In the last years, the biological targets of anticancer agents have started to be clearer and one of these main targets is tubulin protein; this protein plays an essential role in cell division, as well as in intracellular transportation. The inhibition of microtubule formation by targeting tubulin protein induces cell death by apoptosis. In the last years, numerous novel structures were designed and synthesized to target tubulin, and this can be achieved by inhibiting the polymerization or depolymerization of the microtubules. In this review article, recent novel compounds that have antiproliferation activities against a panel of cancer cell lines that target tubulin are explored in detail. This review article emphasizes the recent developments of tubulin inhibitors, with insights into their antiproliferative and anti-tubulin activities. A full literature review shows that tubulin inhibitors are associated with properties in the inhibition of cancer cell line viability, inducing apoptosis, and good binding interaction with the colchicine binding site of tubulin. Furthermore, some drugs, such as cabazitaxel and fosbretabulin, have been approved by FDA in the last three years as tubulin inhibitors. The design and development of efficient tubulin inhibitors is progressively becoming a credible solution in treating many species of cancers. MDPI 2022-12-10 /pmc/articles/PMC9776383/ /pubmed/36551271 http://dx.doi.org/10.3390/biom12121843 Text en © 2022 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hawash, Mohammed
Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy
title Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy
title_full Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy
title_fullStr Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy
title_full_unstemmed Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy
title_short Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy
title_sort recent advances of tubulin inhibitors targeting the colchicine binding site for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776383/
https://www.ncbi.nlm.nih.gov/pubmed/36551271
http://dx.doi.org/10.3390/biom12121843
work_keys_str_mv AT hawashmohammed recentadvancesoftubulininhibitorstargetingthecolchicinebindingsiteforcancertherapy